Seres Therapeutics

Cambridge, United States Founded: 2010 • Age: 16 yrs
Microbiome therapeutics are developed to address diverse diseases.
Request Access

About Seres Therapeutics

Seres Therapeutics is a company based in Cambridge (United States) founded in 2010 by David Berry.. Seres Therapeutics has raised $257.13 million across 9 funding rounds from investors including ARE, Flagship Pioneering and Nestlé Health Science. The company has 103 employees as of December 31, 2024. Seres Therapeutics offers products and services including Live Biotherapeutics and GoodNature Program. Seres Therapeutics operates in a competitive market with competitors including Biogen, Denali Therapeutics, UCB, Grifols and MiRagen, among others.

  • Headquarter Cambridge, United States
  • Employees 103 as on 31 Dec, 2024
  • Founders David Berry
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Seres Therapeutics, Inc.
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Healthcare Products & Supplies
Healthcare → Biotechnology, Genomics & Life Sciences Research
Key Metrics
  • Annual Revenue
    $0
    0
    as on Dec 31, 2024
  • Net Profit
    $-146.57 M
    -28.88
    as on Dec 31, 2024
  • EBITDA
    $-103.35 M
    42.58
    as on Dec 31, 2024
  • Total Equity Funding
    $257.13 M (USD)

    in 9 rounds

  • Latest Funding Round
  • Investors
    ARE

    & 6 more

  • Employee Count
    103

    as on Dec 31, 2024

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Seres Therapeutics

Seres Therapeutics is a publicly listed company on the NASDAQ with ticker symbol MCRB in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: NASDAQ · Ticker: MCRB . Sector: Health technology · USA

Products & Services of Seres Therapeutics

Seres Therapeutics offers a comprehensive portfolio of products and services, including Live Biotherapeutics and GoodNature Program. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Treats bacterial infections and GI diseases through innovative biotherapeutics.

Facilitates stool donations for biotherapeutics research and development.

People of Seres Therapeutics
Headcount 200-500
Employee Profiles 70
Board Members and Advisors 12
Employee Profiles
People
Matthew Henn
EVP, Chief Scientific Officer
People
Terri Young
EVP, Chief Commercial & Strategy Officer
People
Thomas J. Desrosier
EVP, Chief Legal Officer & Secretary
People
Marella Thorell
EVP & CFO

Unlock access to complete

Board Members and Advisors
people
Robert Jenq
Scientific Advisory Board
people
Kurt Graves
Board Of Directors; Director

Unlock access to complete

Funding Insights of Seres Therapeutics

Seres Therapeutics has successfully raised a total of $257.13M across 9 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 9
  • Last Round
  • First Round

    (21 Nov 2013)

  • Investors Count 7
Date Amount Transaction Name Valuation Lead Investors Investors
Jun, 2024 Amount Post-IPO - Seres Therapeutics Valuation

investors

Nov, 2017 Amount Grant - Seres Therapeutics Valuation

investors

Jan, 2015 Amount Series D - Seres Therapeutics Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Seres Therapeutics

Seres Therapeutics has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, Flagship Pioneering and Nestlé Health Science. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
-
Founded Year Domain Location
-
Founded Year Domain Location
Life sciences-focused venture capital firm
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Seres Therapeutics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Seres Therapeutics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Seres Therapeutics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Seres Therapeutics

Seres Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, Denali Therapeutics, UCB, Grifols and MiRagen, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Therapies for neurodegenerative and immunology disorders are developed.
domain founded_year HQ Location
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
domain founded_year HQ Location
Therapies for immunological and neurological disorders are developed.
domain founded_year HQ Location
Plasma-derived therapies are developed to treat multiple diseases.
domain founded_year HQ Location
MicroRNA-based therapeutics are developed for treating multiple diseases.
domain founded_year HQ Location
Small molecule protein degraders are developed for various disorders.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Seres Therapeutics

Frequently Asked Questions about Seres Therapeutics

When was Seres Therapeutics founded?

Seres Therapeutics was founded in 2010 and raised its 1st funding round 3 years after it was founded.

Where is Seres Therapeutics located?

Seres Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.

Is Seres Therapeutics a funded company?

Seres Therapeutics is a funded company, having raised a total of $257.13M across 9 funding rounds to date. The company's 1st funding round was a Series D of $65M, raised on Nov 21, 2013.

How many employees does Seres Therapeutics have?

As of Dec 31, 2024, the latest employee count at Seres Therapeutics is 103.

What does Seres Therapeutics do?

Seres Therapeutics was founded in 2010 and is based in Cambridge, United States. Operations center on the biotechnology sector, where microbiome-based therapeutics are created for treating conditions such as C. difficile infection, antibiotic-resistant infections, graft-versus-host disease, and ulcerative colitis. The pipeline includes candidates like SER-109, SER-155, and SER-287, with development focused on clinical advancement and therapeutic applications.

Who are the top competitors of Seres Therapeutics?

Seres Therapeutics's top competitors include Kymeratx, PureTech Health and Poseida Therapeutics.

What products or services does Seres Therapeutics offer?

Seres Therapeutics offers Live Biotherapeutics and GoodNature Program.

Is Seres Therapeutics publicly traded?

Yes, Seres Therapeutics is publicly traded on NASDAQ under the ticker symbol MCRB.

Who are Seres Therapeutics's investors?

Seres Therapeutics has 7 investors. Key investors include ARE, Flagship Pioneering, Nestlé Health Science, CARB-X, and Ludicrous Ventures.

What is Seres Therapeutics's ticker symbol?

The ticker symbol of Seres Therapeutics is MCRB on NASDAQ.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available